A Department of Defense (DoD)-funded Phase 2 clinical study on TapImmune's HER2/neu-targeted T-cell vaccine for women diagnosed with an early form of breast cancer called ductal carcinoma in situ (DCIS)
Phase of Trial: Phase I/II
Latest Information Update: 17 Mar 2017
At a glance
- Drugs TPIV 110 (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 17 Mar 2017 New trial record
- 14 Mar 2017 This study is expected to begin in 2017 and will be led by Keith Knutson, according to a TapImmune media release.
- 14 Mar 2017 The company has received a $3.7 million grant from the US Department of Defense (DoD) to conduct this trial, according to a TapImmune media release.